{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T16:00:51Z","timestamp":1781020851085,"version":"3.54.1"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T00:00:00Z","timestamp":1779753600000},"content-version":"vor","delay-in-days":55,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Can J Anesth\/J Can Anesth"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1007\/s12630-026-03081-y","type":"journal-article","created":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T13:57:47Z","timestamp":1779803867000},"page":"325-341","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A proposed North American approach for genetic testing of individuals at risk for malignant hyperthermia","Proposition d\u2019une approche nord-am\u00e9ricaine pour le d\u00e9pistage g\u00e9n\u00e9tique des personnes \u00e0 risque d\u2019hyperthermie maligne"],"prefix":"10.1007","volume":"73","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0670-1516","authenticated-orcid":false,"given":"Sheila","family":"Riazi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stacey","family":"Watt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Plester","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leslie G.","family":"Biesecker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,26]]},"reference":[{"key":"3081_CR1","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-015-0310-1","volume":"10","author":"H Rosenberg","year":"2015","unstructured":"Rosenberg H, Pollock N, Schiemann A, Bulger T, Stowell K. Malignant hyperthermia: A review. Orphanet J Rare Dis 2015; 10: 93. https:\/\/doi.org\/10.1186\/s13023-015-0310-1","journal-title":"Orphanet J Rare Dis"},{"key":"3081_CR2","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1213\/ANE.0b013e3181c6b9b2","volume":"110","author":"MG Larach","year":"2010","unstructured":"Larach MG, Gronert GA, Allen GC, Brandom BW, Lehman EB. Clinical presentation, treatment, and complications of malignant hyperthermia in North America from 1987 to 2006. Anesth Analg 2010; 110: 498\u2013507. https:\/\/doi.org\/10.1213\/ANE.0b013e3181c6b9b2","journal-title":"Anesth Analg"},{"key":"3081_CR3","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1097\/ALN.0000000000001878","volume":"128","author":"S Riazi","year":"2018","unstructured":"Riazi S, Kraeva N, Hopkins PM. Malignant hyperthermia in the post-genomics era: New perspectives on an old concept. Anesthesiology 2018; 128: 168\u201380. https:\/\/doi.org\/10.1097\/ALN.0000000000001878","journal-title":"Anesthesiology"},{"key":"3081_CR4","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1093\/bja\/aev225","volume":"115","author":"PM Hopkins","year":"2015","unstructured":"Hopkins PM, R\u00fcffert H, Snoeck MM, et al. European Malignant Hyperthermia Group: European Malignant Hyperthermia Group guidelines for investigation of malignant hyperthermia susceptibility. Br J Anaesth 2015; 115: 531\u20139. https:\/\/doi.org\/10.1093\/bja\/aev225","journal-title":"Br J Anaesth"},{"key":"3081_CR5","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1097\/00000542-199803000-00006","volume":"88","author":"GC Allen","year":"1998","unstructured":"Allen GC, Larach MG, Kunselman AR. The sensitivity and specificity of the Caffeine-Halothane Contracture Test: A report from the North American Malignant Hyperthermia Registry. Anesthesiology 1998; 88: 579\u201388. https:\/\/doi.org\/10.1097\/00000542-199803000-00006","journal-title":"Anesthesiology"},{"key":"3081_CR6","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1007\/s12630-018-1250-8","volume":"66","author":"PM Jones","year":"2019","unstructured":"Jones PM, Allen BN, Cherry RA, et al. Association between known or strongly suspected malignant hyperthermia susceptibility and postoperative outcomes: An observational population-based study. Can J Anaesth 2019; 66: 161\u201381. https:\/\/doi.org\/10.1007\/s12630-018-1250-8","journal-title":"Can J Anaesth"},{"key":"3081_CR7","doi-asserted-by":"publisher","first-page":"100866","DOI":"10.1016\/j.gim.2023.100866","volume":"25","author":"DT Miller","year":"2023","unstructured":"Miller DT, Lee K, Abul-Husn NS, et al. ACMG Secondary Findings Working Group: ACMG SF v3.2 list for reporting of secondary findings in clinical exome and genome sequencing: A policy statement of the American College of Medical Genetics and Genomics (ACMG). Genet Med 2023; 25: 100866. https:\/\/doi.org\/10.1016\/j.gim.2023.100866","journal-title":"Genet Med"},{"key":"3081_CR8","doi-asserted-by":"publisher","first-page":"101228","DOI":"10.1016\/j.gim.2024.101228","volume":"27","author":"ClinGen Consortium","year":"2025","unstructured":"ClinGen Consortium. The Clinical Genome Resource (ClinGen): Advancing genomic knowledge through global curation. Genet Med 2025; 27: 101228. https:\/\/doi.org\/10.1016\/j.gim.2024.101228","journal-title":"Genet Med"},{"key":"3081_CR9","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/gim.2015.30","volume":"17","author":"S Richards","year":"2015","unstructured":"Richards S, Aziz N, Bale S, et al. ACMG Laboratory Quality Assurance Committee: Standards and guidelines for the interpretation of sequence variants: A joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med 2015; 17: 405\u201324. https:\/\/doi.org\/10.1038\/gim.2015.30","journal-title":"Genet Med"},{"key":"3081_CR10","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1038\/s41436-021-01125-w","volume":"23","author":"JJ Johnston","year":"2021","unstructured":"Johnston JJ, Dirksen RT, Girard T, et al. Variant curation expert panel recommendations for RYR1 pathogenicity assertions in malignant hyperthermia susceptibility. Genet Med 2021; 23: 1288\u201395. https:\/\/doi.org\/10.1038\/s41436-021-01125-w","journal-title":"Genet Med"},{"key":"3081_CR11","doi-asserted-by":"publisher","first-page":"4087","DOI":"10.1093\/hmg\/ddac145","volume":"31","author":"JJ Johnston","year":"2022","unstructured":"Johnston JJ, Dirksen RT, Girard T, et al. Updated variant curation expert panel criteria and pathogenicity classifications for 251 variants for RYR1-related malignant hyperthermia susceptibility. Hum Mol Genet 2022; 31: 4087\u201393. https:\/\/doi.org\/10.1093\/hmg\/ddac145","journal-title":"Hum Mol Genet"},{"key":"3081_CR12","first-page":"1044","volume":"53","author":"Centers for Disease Control and Pre","year":"2004","unstructured":"Centers for Disease Control and Prevention. Awareness of family health history as a risk factor for disease\u2014 United States, 2004. MMWR Morb Mortal Wkly Rep 2004; 53: 1044\u20137. PMID:15538320","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"3081_CR13","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1111\/j.1468-1331.2010.03012.x","volume":"17","author":"T Kyriakides","year":"2010","unstructured":"Kyriakides T, Angelini C, Schaefer J, et al. European Federation of Neurological Societies: EFNS guidelines on the diagnostic approach to pauci- or asymptomatic hyperCKemia. Eur J Neurol 2010; 17: 767\u201373. https:\/\/doi.org\/10.1111\/j.1468-1331.2010.03012.x","journal-title":"Eur J Neurol"},{"key":"3081_CR14","first-page":"329","volume":"37","author":"HM Binkley","year":"2002","unstructured":"Binkley HM, Beckett J, Casa DJ, Kleiner DM, Plummer PE. National Athletic Trainers\u2019 Association position statement: Exertional heat illnesses. J Athl Train 2002; 37: 329\u201343. PMID:12937591","journal-title":"J Athl Train"},{"key":"3081_CR15","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1097\/ALN.0000000000000732","volume":"123","author":"MA Timmins","year":"2015","unstructured":"Timmins MA, Rosenberg H, Larach MG, Sterling C, Kraeva N, Riazi S. Malignant hyperthermia testing in probands without adverse anesthetic reaction. Anesthesiology 2015; 123: 548\u201356. https:\/\/doi.org\/10.1097\/ALN.0000000000000732","journal-title":"Anesthesiology"},{"key":"3081_CR16","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1097\/00000542-199404000-00008","volume":"80","author":"MG Larach","year":"1994","unstructured":"Larach MG, Localio AR, Allen GC, et al. A clinical grading scale to predict malignant hyperthermia susceptibility. Anesthesiology 1994; 80: 771\u20139. https:\/\/doi.org\/10.1097\/00000542-199404000-00008","journal-title":"Anesthesiology"},{"key":"3081_CR17","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1213\/ANE.0b013e3182937d8b","volume":"118","author":"S Riazi","year":"2014","unstructured":"Riazi S, Larach MG, Hu C, Wijeysundera D, Massey C, Kraeva N. Malignant hyperthermia in Canada: Characteristics of index anesthetics in 129 malignant hyperthermia susceptible probands. Anesth Analg 2014; 118: 381\u20137. https:\/\/doi.org\/10.1213\/ANE.0b013e3182937d8b","journal-title":"Anesth Analg"},{"key":"3081_CR18","doi-asserted-by":"publisher","first-page":"1734","DOI":"10.1002\/humu.24088","volume":"41","author":"SV Tavtigian","year":"2020","unstructured":"Tavtigian SV, Harrison SM, Boucher KM, Biesecker LG. Fitting a naturally scaled point system to the ACMG\/AMP variant classification guidelines. Hum Mutat 2020; 41: 1734\u20137. https:\/\/doi.org\/10.1002\/humu.24088","journal-title":"Hum Mutat"},{"key":"3081_CR19","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.bja.2020.09.029","volume":"126","author":"H R\u00fcffert","year":"2021","unstructured":"R\u00fcffert H, Bastian B, Bendixen D, et al. European Malignant Hyperthermia Group: Consensus guidelines on perioperative management of malignant hyperthermia suspected or susceptible patients from the European Malignant Hyperthermia Group. Br J Anaesth 2021; 126: 120\u201330. https:\/\/doi.org\/10.1016\/j.bja.2020.09.029","journal-title":"Br J Anaesth"},{"key":"3081_CR20","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1097\/ALN.0000000000002813","volume":"131","author":"CA Ibarra Moreno","year":"2019","unstructured":"Ibarra Moreno CA, Hu S, Kraeva N, et al. An assessment of penetrance and clinical expression of malignant hyperthermia in individuals carrying diagnostic ryanodine receptor 1 gene mutations. Anesthesiology 2019; 131: 983\u201391. https:\/\/doi.org\/10.1097\/ALN.0000000000002813","journal-title":"Anesthesiology"},{"key":"3081_CR21","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1097\/ALN.0b013e3182a8a8e7","volume":"119","author":"SG Gonsalves","year":"2013","unstructured":"Gonsalves SG, Ng D, Johnston JJ, et al. NISC Comparative Sequencing Program: Using exome data to identify malignant hyperthermia susceptibility mutations. Anesthesiology 2013; 119: 1043\u201353. https:\/\/doi.org\/10.1097\/ALN.0b013e3182a8a8e7","journal-title":"Anesthesiology"},{"key":"3081_CR22","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1097\/ALN.0000000000004786","volume":"140","author":"KD Yu","year":"2024","unstructured":"Yu KD, Betts MN, Urban GM, et al. Evaluation of malignant hyperthermia features in patients with pathogenic or likely pathogenic RYR1 variants disclosed through a population genomic screening program. Anesthesiology 2024; 140: 52\u201361. https:\/\/doi.org\/10.1097\/ALN.0000000000004786","journal-title":"Anesthesiology"},{"key":"3081_CR23","doi-asserted-by":"publisher","first-page":"2427","DOI":"10.1016\/j.ajhg.2024.09.002","volume":"111","author":"X Yin","year":"2024","unstructured":"Yin X, Richardson M, Laner A, et al. Large-scale application of ClinGen-InSiGHT APC-specific ACMG\/ AMP variant classification criteria leads to substantial reduction in VUS. Am J Hum Genet 2024; 111: 2427\u201343. https:\/\/doi.org\/10.1016\/j.ajhg.2024.09.002","journal-title":"Am J Hum Genet"},{"key":"3081_CR24","doi-asserted-by":"publisher","first-page":"2248","DOI":"10.1038\/s41436-019-0493-2","volume":"21","author":"C Mighton","year":"2019","unstructured":"Mighton C, Charames GS, Wang M, et al. Variant classification changes over time in BRCA1 and BRCA2. Genet Med 2019; 21: 2248\u201354. https:\/\/doi.org\/10.1038\/s41436-019-0493-2","journal-title":"Genet Med"},{"key":"3081_CR25","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1038\/s41436-021-01171-4","volume":"23","author":"DT Miller","year":"2021","unstructured":"Miller DT, Lee K, Gordon AS, et al. ACMG Secondary Findings Working Group: Recommendations for reporting of secondary findings in clinical exome and genome sequencing, 2021 update: A policy statement of the American College of Medical Genetics and Genomics (ACMG). Genet Med 2021; 23: 1391\u20138. https:\/\/doi.org\/10.1038\/s41436-021-01171-4","journal-title":"Genet Med"}],"container-title":["Canadian Journal of Anesthesia\/Journal canadien d'anesth\u00e9sie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12630-026-03081-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12630-026-03081-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12630-026-03081-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T15:24:09Z","timestamp":1781018649000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12630-026-03081-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":25,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["3081"],"URL":"https:\/\/doi.org\/10.1007\/s12630-026-03081-y","relation":{},"ISSN":["0832-610X","1496-8975"],"issn-type":[{"value":"0832-610X","type":"print"},{"value":"1496-8975","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"14 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 November 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 January 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 May 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors thank Drs. Henry Rosenberg, M.D. (Malignant Hyperthermia Association of the United States, Sherbourne, New York), Nikolaus Gravenstein, M.D. (North American Malignant Hyperthermia Registry, University of Florida College of Medicine, Gainesville, Florida), and Mark Poler, M.D. (Geisinger Health System, Danville, Pennsylvania) for critical review of the article. The authors also thank Bryan Penberthy, M.F.A. (Communications and Publishing Office, Department of Anesthesiology, University of Florida College of Medicine, Gainesville, Florida), for editorial assistance with this article.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Acknowledgments"}},{"value":"Dr. Riazi receives salary support through a merit award from the UHN Research Institute (Toronto, Canada). Dr. Biesecker is supported by grant No. 1 ZIA HG200387-11 from the National Institutes of Health, National Human Genome Research Institute Intramural Research (Bethesda, Maryland).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Research Support"}},{"value":"Dr. Biesecker receives research support from Merck, Inc. (Rahway, New Jersey); is a member of the Illumina Corp. (San Diego, California) Medical Ethics Advisory Committee; and receives royalties from Wolters Kluwer for Up-To-Date (Alphen aan den Rijn, Netherlands). Dr. Watt is the President of the Malignant Hyperthermia Association of United States (Sherbourne, New York), and Dr. Riazi is Chair of the International Professional Advisory Council of the Malignant Hyperthermia Association of United States (Sherbourne, New York). Dr. Plester declares no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Les autrices et auteurs remercient le Dr Henry Rosenberg, M.D. (\n                      Malignant Hyperthermia Association of the United States\n                      , Sherbourne, New York), Nikolaus Gravenstein, M.D. (\n                      North American Malignant Hyperthermia Registry\n                      , University of Florida College of Medicine, Gainesville, Floride) et Mark Poler, M.D. (Geisinger Health System, Danville, Pennsylvanie) pour la revue critique de l\u2019article. Nous remercions \u00e9galement Bryan Penberthy, M.F.A. (Bureau des Communications et publications, D\u00e9partement d\u2019anesth\u00e9siologie, University of Florida College of Medicine, Gainesville, Floride), pour son aide \u00e9ditoriale pour cet article.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Remerciements"}},{"value":"La Dre Riazi re\u00e7oit un soutien salarial sous forme de bourse de m\u00e9rite de l\u2019UHN Research Institute (Toronto, Canada). Le Dr Biesecker est soutenu par la subvention no 1 ZIA HG200387-11 des National Institutes of Health, National Human Genome Research Institute, programme de recherche intramurale (Bethesda, Maryland).","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Soutien \u00e0 la recherche"}},{"value":"Le Dr Biesecker re\u00e7oit un soutien \u00e0 la recherche de Merck, Inc. (Rahway, New Jersey), est membre du comit\u00e9 consultatif en \u00e9thique m\u00e9dicale d\u2019Illumina Corp. (San Diego, Californie) et re\u00e7oit des redevances de Wolters Kluwer pour Up-To-Date (Alphen aan den Rijn, Pays-Bas). La Dre Watt est pr\u00e9sidente de la\n                      Malignant Hyperthermia Association of the United States\n                      (Sherbourne, New York), et la Dre Riazi est pr\u00e9sidente du\n                      International Professional Advisory Council\n                      de la\n                      Malignant Hyperthermia Association of the United States\n                      (Sherbourne, New York). La Dre Plester d\u00e9clare n\u2019avoir aucun conflit d\u2019int\u00e9r\u00eats.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflits d\u2019int\u00e9r\u00eat"}}]}}